Aviva PLC lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 109,678 shares of the medical research company's stock after selling 80,258 shares during the period. Aviva PLC owned about 0.06% of IQVIA worth $21,553,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Geode Capital Management LLC lifted its holdings in IQVIA by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after acquiring an additional 77,981 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after purchasing an additional 59,426 shares during the period. Cantillon Capital Management LLC boosted its holdings in shares of IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock valued at $406,018,000 after acquiring an additional 226,017 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.
IQVIA Stock Up 1.5 %
Shares of IQV stock traded up $2.18 during trading on Friday, hitting $145.40. 2,601,630 shares of the company were exchanged, compared to its average volume of 1,384,213. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $25.64 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 1.99 and a beta of 1.46. The business's 50-day simple moving average is $182.32 and its 200 day simple moving average is $199.38.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on IQV. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Barclays reissued an "equal weight" rating and issued a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research note on Thursday. Finally, Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $241.50.
Read Our Latest Stock Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
